Posted by Michael Wonder on 23 Aug 2022
Extra-ordinary meeting of the CHMP: 1 September 2022
23 August 2022 - This extra-ordinary meeting is organised to discuss the evaluation of two applications for adapted mRNA COVID-19 vaccines which more closely match the original strain and the BA.1 Omicron subvariant.
One application was submitted by Moderna for Spikevax (previously COVID-19 Vaccine Moderna) and one by Pfizer/BioNTech for Comirnaty.
The aim of the meeting is to conclude the evaluation of the two applications, if possible.
